Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells

Cai, Fengfeng; Ge, Isabell; Wang, Minghong; Biskup, Ewelina; Lin, Xinhua; Zhong, Xiaoyan

doi:10.1007/s13277-013-1508-2

Cited by 15 publications

(11 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, several lines of evidences confirmed that the expression pattern of sporadic BRCA1 -methylated breast cancers was the same as that of inherited BRCA1 mutations 52 . Herein, numerous preclinical researches investigated whether the antitumor activity of DNA-damaging agents in BRCA1 -mutated breast cancers had a similar activity in BRCA1 -methylated tumors, and the results demonstrated that the BRCA1 hypermethylation conferred the same extent of sensitivity to poly adeno-sine diphosphate-ribose polymerase-1 (PARP1) inhibitors and platinum-derived drugs as did the BRCA1 mutation 53 54 55 . Moreover, Xu et al reported that BRCA1 -methylated triple-negative breast tumor patients were sensitive to adjuvant chemotherapy and had a significantly better 10-year disease-free survival (DFS) and disease-specific survival (DSS) than patients with BRCA1 -unmethylated triple-negative tumors 46 .…”

Section: Discussionmentioning

confidence: 99%

Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies

Zhang

Long

2015

Sci Rep

View full text Add to dashboard Cite

Breast cancer susceptibility gene 1 (BRCA1) located at chromosome 17q12-21 is a classic tumor suppressor gene, and has been considered as a significant role in hereditary breast cancers. Moreover, numerous studies demonstrated the methylation status of CpG islands in the promoter regions of BRCA1 gene was aberrant in patients with sporadic breast tumors compared with healthy females or patients with benign diseases. However, these conclusions were not always consistent. Hence, a meta-analysis was performed to get a more precise estimate for these associations. Crude odds ratio with 95% confidence interval were used to assess the association of BRCA1 promoter methylation and the risk or clinicopathologic characteristics of breast cancers under fixed or random effect model. A total of 40 studies were eligible for this present study. We observed the frequency of BRCA1 promoter methylation was statistically significant higher in breast cancers than non-cancer controls. Furthermore, BRCA1 methylation was statistically associated with lymph node metastasis, histological grade 3, ER(-), PR(-), triple-negative phenotype, and decreased or lack levels of BRCA1 protein expression. In conclusion, this study indicated that BRCA1 promoter methylation appeared to be a useful predictive or prognostic biomarker for breast cancers in clinical assessment.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies

Zhang

Long

2015

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Importantly, they used peripheral blood as diagnostic specimen for the determination of methylation status of BRCA1 promoter, which could be therefore used as a screening tool ( 41 ). Promoter hypermethylation of BRCA1 could serve also as predictive biomarker for PARP1 inhibitor therapy, which has been currently used only for treatment of patients with BRCA1 and BRCA2 mutations to decrease the growth and vascularisation of tumour ( 42 ). …”

Section: Breast Cancermentioning

confidence: 99%

Aberrant methylation patterns in cancer: a clinical view

Paska

Hudler

2015

Biochem Med

View full text Add to dashboard Cite

Epigenetic mechanisms, such as DNA methylation, DNA hydroxymethylation, post-translational modifications (PTMs) of histone proteins affecting nucleosome remodelling, and regulation by small and large non-coding RNAs (ncRNAs) work in concert with cis and trans acting elements to drive appropriate gene expression. Advances in detection methods and development of dedicated platforms and methylation arrays resulted in an explosion of information on aberrantly methylated sequences linking deviations in epigenetic landscape with the initiation and progression of complex diseases. Here, we consider how DNA methylation changes in malignancies, such as breast, pancreatic, colorectal, and gastric cancer could be exploited for the purpose of developing specific diagnostic tools. DNA methylation changes can be applicable as biomarkers for detection of malignant disease in easily accessible tissues. Methylation signatures are already proving to be an important marker for determination of drug sensitivity. Even more, promoter methylation patterns of some genes, such as MGMT, SHOX2, and SEPT9, have already been translated into commercial clinical assays aiding in patient assessment as adjunct diagnostic tools. In conclusion, the changes in DNA methylation patterns in tumour cells are slowly gaining entrance into routine diagnostic tests as promising biomarkers and as potential therapeutic targets.

show abstract

“…BRCA1 promoter methylation has also been proposed as a marker for HR deficiency, as functional methylation of the BRCA1 promoter leads to repression of BRCA1 mRNA expression [55,56]. Specific assays to detect BRCA1 promoter methylation in clinical cancer samples, including tumor biopsies, have been developed and validated [57].…”

Section: Predictive Biomarkers For Parp Inhibitor Sensitivitymentioning

confidence: 99%

Parp Inhibitors: The Journey from Research Hypothesis to Clinical Approval

Naipal

Gent

2015

Per. Med.

View full text Add to dashboard Cite

Cancer puts an increasing burden on our healthcare system and is a major cause of death. Therefore, novel approaches are required to improve cancer treatment. Cancer cells have several hallmarks that could be therapeutically targeted. Importantly, every tumor has a different combination of aberrations affecting the different hallmarks. This review focuses on targeting one of these hallmarks, the DNA damage response (DDR). DDR defects can not only cause cancer, but they can also be exploited therapeutically. This plays an important role even in 'classical' (DNA damaging) chemotherapy and radiotherapy, but more precise targeting of specific defects is expected to increase treatment efficacy and decrease normal tissue toxicity. Poly-(ADP-ribose) polymerase (PARP) inhibitors are the first clinical example of such synthetic lethality in tumors having specific DDR defects. They are currently under investigation as DDR-targeting anticancer drugs and they progress quickly in clinical trials.

show abstract

Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells

Cited by 15 publications

References 27 publications

Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies

Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies

Aberrant methylation patterns in cancer: a clinical view

Parp Inhibitors: The Journey from Research Hypothesis to Clinical Approval

Contact Info

Product

Resources

About